TY - JOUR
T1 - Magnetic Resonance–Guided Focused Ultrasound Treatment for Essential Tremor
T2 - A Single-Center Experience
AU - Hvingelby, Victor
AU - Kjeldsen, Pernille Louise
AU - Bergholt, Bo
AU - Schechtmann, Gastón
AU - Danielsen, Erik Hvid
AU - Møller, Mette
AU - Johnsen, Erik Lisbjerg
AU - Mardosiene, Skirmante
AU - Lund, Torben Ellegaard
AU - Grauballe, Dora
AU - Geneser, Michael
AU - Sørensen, Tina Vincens
AU - Bak, Lisa Østergaard
AU - Andreasen, Martin
AU - Andersen, Anne Sofie Møller
AU - Andersen, Lone
AU - Meier, Kaare
AU - Juhl, Niels
AU - Tankisi, Alp
AU - Jespersen, Bo
AU - Fenger-Eriksen, Christian
AU - Rasmussen, Mads
AU - Bechmann Eriksen, Winnie
AU - Barrutia, Birgitte
AU - Kromann, Mette
AU - Baandrup, Ida
AU - Bjørn, Jette
AU - Stjernholm, Rie
AU - Braemer-Madsen, Charlotte
AU - Jørgensen, Signe Mygdal
AU - Sørensen, Jens Christian Hedemann
AU - Glud, Andreas
N1 - Publisher Copyright:
© 2025 The Author(s). Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
PY - 2025/2/19
Y1 - 2025/2/19
N2 - Background: Essential tremor is the most common hyperkinetic movement disorder. Magnetic resonance imaging–guided focused ultrasound (MRgFUS) has emerged as second-line therapy. Objective: The aim was to obtain the results of the first 108 patients treated with MRgFUS in Denmark. Methods: Data were entered in a quality assurance database at baseline and 3, 6, and 12 months. Clinician- and patient-rated treatment efficacy was evaluated using the Fahn–Marin–Tolosa (FMT) scale and the Patient Global Impression of Change. Results: A total of 108 persons have currently been treated. Tremor improved by a total mean 6.39 points (95% confidence interval [CI]: 5.01;7.76, P < 0.00001) and 9.63 points (95% CI: 7.60;11.66, P < 0.00001), 10.42 (95% CI: 9.06;11.79, P < 0.00001), and 26.45 (95% CI: 22.46;30.43, P < 0.00001) for FMT parts A, B, and C, respectively, at 3 months. Side effects occurred in 65.7% of patients at 3 months and 33.7% at 12 months. Conclusion: Our findings are in line with existing evidence. Questions regarding persistence of gait- and balance-related side effects remain.
AB - Background: Essential tremor is the most common hyperkinetic movement disorder. Magnetic resonance imaging–guided focused ultrasound (MRgFUS) has emerged as second-line therapy. Objective: The aim was to obtain the results of the first 108 patients treated with MRgFUS in Denmark. Methods: Data were entered in a quality assurance database at baseline and 3, 6, and 12 months. Clinician- and patient-rated treatment efficacy was evaluated using the Fahn–Marin–Tolosa (FMT) scale and the Patient Global Impression of Change. Results: A total of 108 persons have currently been treated. Tremor improved by a total mean 6.39 points (95% confidence interval [CI]: 5.01;7.76, P < 0.00001) and 9.63 points (95% CI: 7.60;11.66, P < 0.00001), 10.42 (95% CI: 9.06;11.79, P < 0.00001), and 26.45 (95% CI: 22.46;30.43, P < 0.00001) for FMT parts A, B, and C, respectively, at 3 months. Side effects occurred in 65.7% of patients at 3 months and 33.7% at 12 months. Conclusion: Our findings are in line with existing evidence. Questions regarding persistence of gait- and balance-related side effects remain.
KW - Essential tremor
KW - Focused ultrasound
KW - Magnetic resonance imaging
UR - http://www.scopus.com/inward/record.url?scp=85219730605&partnerID=8YFLogxK
U2 - 10.1002/mdc3.70012
DO - 10.1002/mdc3.70012
M3 - Journal article
C2 - 39968962
AN - SCOPUS:85219730605
SN - 2330-1619
JO - Movement Disorders Clinical Practice
JF - Movement Disorders Clinical Practice
ER -